Start here if you're new
what it is
Akebia sells kidney-disease medicines and is trying to turn one approved drug into a bigger business.
how it gets paid
Full-year 2025 net product revenue was ~$227.3M, up ~49% vs. 2024 (company release).
why it's growing
The ~49% full-year jump is the story: Vafseo is carrying the top line while Auryxia fades on generics.
what just happened
Q4 2025 net product revenue was ~$54.3M; the quarter was a modest diluted EPS miss vs. consensus (loss per share, not a clean positive print).
At a glance
B balance sheet — gets the job done, barely
45/100 earnings predictability — expect surprises
0.1x trailing p/e — the market's not buying it — or you found a deal
-$0.33 fy2024 eps est
$160M fy2024 rev est
xvary composite: 48/100 — below average
What they do
Akebia sells kidney-disease medicines and is trying to turn one approved drug into a bigger business.
Vafseo is approved in 37 countries, and Akebia has 181 employees. That is a small crew carrying a wide footprint. Your edge is that one approved drug can do more work than the rest of the pipeline.
How they make money
~$227M
FY2025 net product revenue · ~+49% vs. prior year (company release)
net product revenue
~$227M
~+49%
The products that matter
oral anemia treatment
Vafseo (vadadustat)
growth engine · ~290K patients reached (Q4'25)
this is the growth engine. the company cited ~290,000 patients with access to Vafseo in Q4 2025. Vafseo also represents the bulk of the ~$227M net product revenue year—if that patient count keeps climbing, the launch works. if it stalls, the rest of the story gets very short.
make or break
legacy phosphate binder
Auryxia
legacy revenue · still a meaningful mix slice
this used to be the base business. now it is the melting ice cube. generics pushed revenue down roughly 20%, and Auryxia is still a large share of the ~$227M net product revenue base—so total sales can fall even if Vafseo grows.
generic pressure
early kidney pipeline
Rare Kidney Disease Pipeline
phase 2 · 2026 starts · 2027 data
three rare kidney disease programs are expected to enter phase 2 in 2026 across IgAN, lupus nephritis, and C3G. that is real optionality, but it is still future tense. no readout is expected until 2027.
long-dated upside
Key numbers
~$227M
FY2025 net product revenue
Company-reported net product revenue for 2025; the launch curve is visible in the full-year number, not a mismatched quarterly headline.
~$48M
long-term debt (Dec 2025)
Balance-sheet debt is modest vs. the old ~$179M confusion (that figure was not consolidated long-term debt in recent screens). Pair with cash ~$185M in filings.
~$(0.05)
Q4'25 diluted EPS (approx.)
Q4 was still a loss-making quarter on a per-share basis—revenue can beat while EPS misses on costs and mix.
37 countries
Vafseo approvals
Vafseo is approved in 37 countries. One drug now has more passports than most funds.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt ~$48M long-term debt (verify current 10-Q)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for AKBA right now.
source: institutional data · return history unavailable
What just happened
mixed vs. estimates
Q4 2025 net product revenue ~$54.3M; diluted EPS was a small loss vs. a breakeven-tilted consensus.
Full-year net product revenue reached ~$227.3M (+49%). Vafseo reached ~290K patients with access in Q4 per the release—the commercial handoff from Auryxia is the operating story.
~$54.3M
Q4 net product revenue
loss
Q4 diluted EPS
~290K
Vafseo patients (Q4)
why the mix matters
Top line can clear the bar while EPS lags—check the same GAAP/adjusted lane as the press release and 10-K.
source: Akebia Q4 & FY2025 results (Mar 2026 fact-check)
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Vafseo adoption stalling before it can replace Auryxia's generic-driven decline.
med
Auryxia shrinks faster than the launch ramps
Auryxia is still a large share of the ~$227M net product revenue base. Generic pressure already pushed that line down roughly 20% year over year in management commentary. If the decline steepens, total company revenue can still fall even while Vafseo grows.
Another roughly $30M hit would matter in a business with only ~$227M of net product revenue.
med
Vafseo growth slows before the model reaches escape velocity
Management does not need Vafseo to merely grow. It needs Vafseo to grow fast enough to fund the company. With ~290,000 patients reached in Q4 and Vafseo carrying most of the ~$227M net product revenue year, the stock lives on whether that curve keeps climbing in 2026.
If Vafseo cannot add at least roughly $50M in 2026, flat company revenue gets harder to defend and the financing question gets louder.
med
The pipeline is too far away to bail out a weak commercial year
Phase 2 studies in IgAN, lupus nephritis, and C3G are expected to start in 2026, but readouts are not expected until 2027. That leaves a long stretch where quarterly commercial numbers matter more than pipeline promise.
No meaningful pipeline data until 2027 means the stock likely trades quarter to quarter on launch evidence, losses, and cash confidence.
roughly 36.5% of revenue still comes from the declining drug, while the company carries $179M in long-term debt and lost $12.2M last quarter. the handoff is happening, but it is not complete. if Vafseo does not absorb that gap fast enough, dilution risk stops being a side risk and becomes the story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
next earnings
Q1 2026 earnings — expected May 14, 2026
This is the first hard check on whether 2026 Vafseo momentum is real. If quarterly product revenue clears $60M, the launch story stays intact. If it slips below $50M, the market will notice.
biggest catalyst
Vafseo prescription trend
Quarterly patient and prescription traction is the leading indicator. Revenue tells you what happened. Adoption tells you what happens next.
risk to watch
financing pressure and dilution risk
The company lost ~$12M in Q4 and carries modest balance-sheet debt (~$50M long-term in recent screens). If Vafseo growth disappoints, capital raising gets more likely. At low single-digit dollars, dilution would not be subtle.
pipeline milestone
phase 2 study starts in 2026
IgAN, lupus nephritis, and C3G programs are expected to move into phase 2 in 2026. That matters as proof the pipeline is progressing, even if the real valuation impact waits until 2027 data.
Analyst rankings
earnings predictability
45 / 100
Below average predictability. in human-speak, analysts do not have a clean model here because one drug is ramping, one is declining, and the company is still losing money.
coverage quality
limited
Thin coverage means estimates can swing around more than the business itself. For you, that means consensus is a rough map, not a GPS.
source: institutional data
Institutional activity
institutional ownership data for AKBA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive